Tinea Pedis (Athlete's Foot): Market Research Report

August 2010 | 269 pages | ID: TAFBF54053DEN
Global Industry Analysts, Inc

Abstracts

This report analyzes the US market for Tinea Pedis (Athlete's Foot) in US$ Million.

Annual estimates and forecasts are provided for the period of 2006 through 2015.

The report profiles 43 companies including many key and niche players such as Hisamitsu Pharmaceutical Co., Inc., Johnson & Johnson, Kaken Pharmaceutical Co., Ltd., Merck & Co., Inc., Nitric BioTherapeutics, Inc., Novartis AG, Sanofi-Aventis, Stiefel Laboratories, Inc., and Topica Pharmaceuticals, Inc.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

Contents

I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. A US MARKET REPORT

1.INDUSTRY OVERVIEW

A Curtain Raiser
Distribution and Prevalence of Tinea Pedis

Table 1. Global Tinea Pedis (Athlete's Foot) Market (2009E): Percentage Breakdown of Global Prevalence of Fungal Infections of the Skin by Country – France, Germany, Italy, UK, US, and Japan (includes corresponding Graph/Chart)

Statistical Insights
Foot Facts & Figures
Current and Future Analysis

Table 2. US Recent Past, Current and Future Analysis for Tinea Pedis (Athlete’s Foot) with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Market Dynamics
Introduction of Novel Formulations Spurs Demand
Aging Population Revs up Anti-Fungal Market

Table 3. US Population by Age Group: 2010E (includes corresponding Graph/Chart)

Market Challenges
Time Consuming Clinical Trials Stall Growth

Table 4. Tinea Pedis (Athlete's Foot) Products by Different Phases of Development (2009) - Marketed Products, Discontinued Projects, Phase I Trials, Phase II Trials, and Under Development (includes corresponding Graph/Chart)

Low Levels of Patient Compliance Reduces Revenue Potential
Lack of Public Awareness Prevents Market Growth
Key Statistical Findings

Table 5. Global Dermatology Market (2009) – Number of Marketed and Pipeline Products in Phase I, II and III Globally Available By Indication - Skin Infections, Skin Disorders, Acne, Skincare, Wounds, and Tinea Pedis (includes corresponding Graph/Chart)

Table 6. Global Tinea Pedis (Athlete's Foot) Market (2009): Number of Available Marketed Products for Tinea Pedis (Athlete's Foot) by Company - Hisamitsu Pharmaceutical Co., Inc., Johnson & Johnson, Kobayashi Pharmaceutical Co., Ltd., Novartis AG, and Taisho Pharmaceutical Co., Ltd. (includes corresponding Graph/Chart)

2.AN OVERVIEW OF TINEA PEDIS (ATHLETE'S FOOT)

An Introduction
Types
Moccasin Tinea Pedis
Interdigital Tinea Pedis
Inflammatory or Bullous Tinea Pedis
Contagious Nature of the Disease
Person to Person
Transmission to Other Body Parts
Object to Person
Animal to Person
Causes of Foot Rashes
Symptoms
Diagnosis
Importance of Timely Diagnosis
Preventive Measures
At Home
At Public Places
Personal Preventive Measures
Treatments
Traditional Treatment
Topical Medications
Oral Medications
Identifying Optimal Formulation
Alternative Treatment
Treatment Process
Complications
Conclusion

3.SELECT DRUGS AVAILABLE FOR TINEA PEDIS

Oral and Topical Agents for Tinea Pedis
Select Anti-Fungal OTC and Prescription Drugs Available by the Mechanism of Action
Review of Select Treatments
Ertaczo (Sertaconazole Nitrate)
Lamisil® (Terbinafine)
Lotrimin Ultra (Butenafine)
Naftin (Naftifine Hydrochloride)
Oxistat (Oxiconazole Nitrate)
Penlac®

4.RESEARCH AND DEVELOPMENT

Clinical Trials
Nitric BioTherapeutics Starts Phase II Onychomycosis Study
Topica Pharmaceuticals Begins Phase 2 Clinical Trial of Luliconazole
Other Research & Development Initiatives

5.RECENT INDUSTRY ACTIVITY

Sanofi Acquires Chattem
Topica Pharmaceuticals Gets FDA Approval for Luliconazole IND (US)
Nitric BioTherapeutics Purchase New Technology Platform and Advanced Clinical Programs
Ranbaxy Laboratories Introduces Lulifin (India)
Schering-Plough Launches Tinactin Chill
Paddock Laboratories Receives FDA Approval for Ciclopirox Gel
Peng Lai Jin Chuang Pharmaceutical Receives Production Approval from SFDA (China)

6.FOCUS ON KEY PLAYERS

Hisamitsu Pharmaceutical Co., Inc. (Japan)
Johnson & Johnson (US)
Kaken Pharmaceutical Co., Ltd. (Japan)
Merck & Co., Inc. (US)
Nitric BioTherapeutics, Inc. (US)
Novartis AG (Switzerland)
Sanofi-Aventis (France)
Stiefel Laboratories, Inc. (US)
Topica Pharmaceuticals, Inc. (US)

III. COMPETITIVE LANDSCAPE

Total Companies Profiled: 43 (including Divisions/Subsidiaries - 50)
Region/CountryPlayers
The United States
Japan
Europe
France
Germany
The United Kingdom
Spain
Rest of Europe
Asia-Pacific (Excluding Japan)
Latin America
Africa
Middle-East